$Molecular (MOLN.US)$ NEWS Molecular Partners Announces Publ...
NEWS
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
Preclinical data shows preferential T cell-mediated killing of AML cells by MP0533 while sparing healthy cells.
MP0533 induces tumor regression and T-cell activation without systemic adverse effects.
The data supports the clinical development of MP0533 as a potential treatment for acute myeloid leukemia.
The ongoing Phase 1/2a clinical study continues to progress well, dosing patients in cohort 7.
MP0533 induces tumor regression and T-cell activation without systemic adverse effects.
The data supports the clinical development of MP0533 as a potential treatment for acute myeloid leukemia.
The ongoing Phase 1/2a clinical study continues to progress well, dosing patients in cohort 7.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow